title: Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-3 receptor agonist versus antagonist activity.
abstract: The melanocortin-3 and -4 receptors (MC3R, MC4R) have been implicated in energy homeostasis and obesity. Whereas the physiological role of the MC4R is extensively studied, little is known about the MC3R. One caveat is the limited availability of ligands that are selective for the MC3R. Previous studies identified Ac-His-DPhe(p-I)-Arg-Trp-NH 2, which possessed partial agonist/antagonist pharmacology at the mMC3R while retaining full nanomolar agonist pharmacology at the mMC4R. These data allowed for the hypothesis that the DPhe position in melanocortin tetrapeptides can be used to examine ligand side-chain determinants important for differentiation of mMC3R agonist versus antagonist activity. A series of 15 DPhe (7) modified Ac-His-DPhe (7)-Arg-Trp-NH 2 tetrapeptides has been synthesized and pharmacologically characterized. Most notable results include the identification of modifications that resulted in potent antagonists/partial agonists at the mMC3R and full, potent agonists at the mMC4R. These SAR studies provide experimental evidence that the molecular mechanism of antagonism at the mMC3R differentiates this subtype from the mMC4R.
authors.affiliation: Department of Pharmacodynamics, University of Florida, Gainesville, Florida 32610, USA.
authors.forename: Bettina
authors.initials: B
authors.lastname: Proneth
authors.forename: Irina D
authors.initials: ID
authors.lastname: Pogozheva
authors.forename: Federico P
authors.initials: FP
authors.lastname: Portillo
authors.forename: Henry I
authors.initials: HI
authors.lastname: Mosberg
authors.forename: Carrie
authors.initials: C
authors.lastname: Haskell-Luevano
mesh_terms: D000818:Animals; D053486:Melanocortins / Q000737:chemistry* / Q000494:pharmacology; D051379:Mice; D044104:Receptor, Melanocortin, Type 3 / Q000819:agonists* / Q000037:antagonists & inhibitors; D055672:Static Electricity; D013329:Structure-Activity Relationship
chemical_list: D053486:Melanocortins; D044104:Receptor, Melanocortin, Type 3
references.citation: J Med Chem. 2002 Jun 20;45(13):2801-10
references.pmid: 12061882
references.citation: Nature. 1994 Oct 27;371(6500):799-802
references.pmid: 7935841
references.citation: Nat Genet. 1998 Oct;20(2):113-4
references.pmid: 9771699
references.citation: Mol Endocrinol. 1994 Oct;8(10):1298-308
references.pmid: 7854347
references.citation: Endocrinology. 2000 Sep;141(9):3518-21
references.pmid: 10965927
references.citation: Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41
references.pmid: 11517324
references.citation: Cell. 1997 Jan 10;88(1):131-41
references.pmid: 9019399
references.citation: Science. 1992 Aug 28;257(5074):1248-51
references.pmid: 1325670
references.citation: Anal Biochem. 1995 Apr 10;226(2):349-54
references.pmid: 7793637
references.citation: Nat Genet. 1998 Oct;20(2):111-2
references.pmid: 9771698
references.citation: J Biol Chem. 1997 Sep 12;272(37):23000-10
references.pmid: 9287296
references.citation: Bioorg Med Chem Lett. 2003 Feb 24;13(4):649-52
references.pmid: 12639550
references.citation: J Med Chem. 2006 Feb 9;49(3):911-22
references.pmid: 16451057
references.citation: Biochemistry. 2005 Aug 30;44(34):11329-41
references.pmid: 16114870
references.citation: Hypertension. 2003 Nov;42(5):962-7
references.pmid: 14568996
references.citation: Biochemistry. 2005 Nov 8;44(44):14494-508
references.pmid: 16262250
references.citation: J Med Chem. 2006 Mar 23;49(6):1946-52
references.pmid: 16539382
references.citation: Br J Pharmacol Chemother. 1947 Sep;2(3):189-206
references.pmid: 20258355
references.citation: Anal Biochem. 1970 Apr;34(2):595-8
references.pmid: 5443684
references.citation: Biochemistry. 2000 Dec 5;39(48):14900-11
references.pmid: 11101306
references.citation: Biochemistry. 2006 Jan 31;45(4):1128-37
references.pmid: 16430209
references.citation: J Clin Invest. 2003 Apr;111(8):1251-8
references.pmid: 12697744
references.citation: J Biol Chem. 1993 Apr 15;268(11):8246-50
references.pmid: 8463333
references.citation: Trends Endocrinol Metab. 2000 Oct;11(8):304-8
references.pmid: 10996524
references.citation: J Med Chem. 1995 Sep 1;38(18):3454-61
references.pmid: 7658432
references.citation: Nat Genet. 1995 Nov;11(3):328-30
references.pmid: 7581459
references.citation: J Med Chem. 2002 Jul 4;45(14):3073-81
references.pmid: 12086493
references.citation: J Biol Chem. 1993 Jul 15;268(20):15174-9
references.pmid: 8392067
references.citation: J Med Chem. 2000 Dec 28;43(26):4998-5002
references.pmid: 11150170
references.citation: Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R560-7
references.pmid: 16195498
references.citation: Endocr Rev. 1980 Winter;1(1):1-27
references.pmid: 6262069
references.citation: J Pharmacol Exp Ther. 2003 Mar;304(3):1217-27
references.pmid: 12604699
references.citation: Bioorg Med Chem Lett. 2007 May 1;17(9):2492-8
references.pmid: 17314042
references.citation: J Biol Chem. 1976 Jul 10;251(13):4115-20
references.pmid: 180015
references.citation: Biochemistry. 2001 May 22;40(20):6164-79
references.pmid: 11352754
references.citation: Nat Genet. 2000 Sep;26(1):97-102
references.pmid: 10973258
references.citation: J Med Chem. 1989 Dec;32(12):2555-61
references.pmid: 2555512
references.citation: J Med Chem. 2002 Dec 19;45(26):5736-44
references.pmid: 12477357
references.citation: Gen Comp Endocrinol. 1989 Jan;73(1):157-63
references.pmid: 2537778
references.citation: Biotechniques. 1988 Jul-Aug;6(7):632-8
references.pmid: 3273409
references.citation: Cell. 1993 Mar 26;72(6):827-34
references.pmid: 8458079
references.citation: Peptides. 2003 Jan;24(1):73-82
references.pmid: 12576087
references.citation: Drug Des Discov. 1996 Dec;14(3):197-211
references.pmid: 9017363
references.citation: J Med Chem. 1987 Nov;30(11):2126-30
references.pmid: 2822931
references.citation: Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8856-60
references.pmid: 8415620